Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course

Immune checkpoint inhibitors (ICIs) are a revolutionary breakthrough in the field of cancer by modulating patient’s own immune system to exert anti-tumor effects. The clinical application of ICIs is still in its infancy, and their dosing regimens need to be continuously adjusted. Pharmacokinetic/pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Mengjie, Hu, Yujie, Lin, Gang, Chen, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251517/
https://www.ncbi.nlm.nih.gov/pubmed/35795044
http://dx.doi.org/10.3389/fonc.2022.906251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251517/
https://www.ncbi.nlm.nih.gov/pubmed/35795044
http://dx.doi.org/10.3389/fonc.2022.906251

Ejemplares similares